The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Veracyte Inc shares valued at $463,204 were sold by McGuire Annie on Dec 16 ’25. At $43.13 per share, McGuire Annie sold 10,739 shares. The insider’s holdings dropped to 67,760 shares worth approximately $2.93 million following the completion of this transaction.
Also, ANN MCGUIRE purchased 10,739 shares, netting a total of over 467,469 in proceeds.
Before that, EASTHAM KARIN had sold 20,000 shares from its account. In a trade valued at $908,923, the Director traded Veracyte Inc shares for $45.45 each. Upon closing the transaction, the insider’s holdings decreased to 20,000 shares, worth approximately $0.59 million.
Analysts at Canaccord Genuity started covering the stock with ‘”a Hold”‘ outlook in a report released in mid October. As of March 20, 2025, Craig Hallum has initiated its “Buy” rating for VCYT. Earlier on December 05, 2024, Goldman downgraded its rating. Their new recommendation was “a Neutral” for VCYT stock which previously was a “a Buy”.
Analyzing VCYT Stock Performance
On last trading session, Veracyte Inc [NASDAQ: VCYT] rose 3.86% to $43.3. The stock’s lowest price that day was $41.2301, but it reached a high of $43.6 in the same session. During the last five days, there has been a surge of approximately 0.58%. Over the course of the year, Veracyte Inc shares have jumped approximately 6.70%.
Is Veracyte Inc subject to short interest?
Stocks of Veracyte Inc saw a sharp steep in short interest on 2025-12-31 dropping by -0.72 million shares to 4.99 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 5.71 million shares. A decline of -14.38% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.49 of the overall float, the days-to-cover ratio (short ratio) decline to 6.49.
Which companies own the most shares of Veracyte Inc (VCYT)?
In terms of Veracyte Inc share price expectations, FactSet research, analysts set an average price target of 48 in the next 12 months, up nearly 15.14% from the previous closing price of $41.69. Analysts anticipate Veracyte Inc stock to reach 50 by 2026, with the lowest price target being 43. In spite of this, 0 analysts ranked Veracyte Inc stock as nan at the end of 2026. On November 15, 2024, Wolfe Research assigned a price target of “an Outperform” to the stock and initiated coverage with a $50.
